Imuran Side Effects

Generic Name: azathioprine

Note: This page contains information about the side effects of azathioprine. Some of the dosage forms included on this document may not apply to the brand name Imuran.

Not all side effects for Imuran may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to azathioprine: oral tablet

In addition to its needed effects, some unwanted effects may be caused by azathioprine (the active ingredient contained in Imuran). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking azathioprine:

More common
  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • chest pain
  • cough or hoarseness
  • fever or chills
  • lower back or side pain
  • painful or difficult urination
  • pinpoint red spots on the skin
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Rare
  • Abdominal or stomach pain or tenderness
  • clay-colored stools
  • dark urine
  • decreased appetite
  • fast heartbeat
  • fever (sudden)
  • headaches
  • itching
  • loss of appetite
  • muscle or joint pain
  • nausea, vomiting, and diarrhea (severe)
  • redness or blisters on the skin
  • swelling of the feet or lower legs
  • unusual feeling of discomfort or illness (sudden)
  • yellow eyes or skin
Incidence not known
  • Abdominal or stomach cramps
  • diarrhea
  • difficulty with breathing
  • difficulty with moving
  • fat in the stool
  • general feeling of illness
  • pale skin
  • sores on the skin
  • sudden loss of weight
  • troubled breathing with movement
  • weight loss

Some of the side effects that can occur with azathioprine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Nausea or vomiting (mild)
  • swollen joints
Incidence not known
  • Hair loss or thinning of the hair

For Healthcare Professionals

Applies to azathioprine: compounding powder, intravenous powder for injection, oral tablet

General

The principal and potentially serious toxic effects of azathioprine (the active ingredient contained in Imuran) are hematologic and gastrointestinal. Risk of secondary infection and malignancy is also significant. Frequency and severity of side effects depend on dose and duration of azathioprine as well as on underlying disease or concomitant therapies. Hematologic toxicities and neoplasia were reported more often in renal homograft recipients than in patients using azathioprine for rheumatoid arthritis.[Ref]

Hematologic

Very common (10% or more): Depression of bone marrow function, leukopenia
Common (1% to 10%): Thrombocytopenia, anemia
Rare (Less than 0.1%): Agranulocytosis, pancytopenia, aplastic anemia, megaloblastic anemia, erythroid hypoplasia
Frequency not reported: Bleeding, increased mean corpuscular volume and red cell hemoglobin content (reversible, dose-related)[Ref]

Bone marrow suppression is dose related and is the most common cause for dosage reductions. Leukopenia (any degree) has been reported in greater than 50% of renal homograft recipients and 28% of rheumatoid arthritis patients. Leukopenia (less than 2500/mm3 [2.5 x 10(9)/L]) has been reported in 16% of renal homograft recipients and 5.3% of rheumatoid arthritis patients.

There are data to support an increased risk of bone marrow aplasia in patients with very low or absent thiopurine methyltransferase (TPMT) activity. In patients with low TPMT activity, there is an increase in 6-thioguanine nucleotide (6-TGN) concentrations, a cytotoxic metabolite which suppresses purine synthesis. Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine. Bone marrow aplasia has been reported in patients with normal TPMT activity.

A 55-year-old male with pompholyx and deficiency of erythrocyte thiopurine methyltransferase experienced pancytopenia coincident with azathioprine therapy. Ten weeks after starting azathioprine 100 mg per day, a full blood count (during routine monitoring) showed moderate pancytopenia. Azathioprine was discontinued. Ten days later he was admitted to the hospital with malaise, lethargy, and deterioration in blood count. He was treated with blood and platelet transfusions and discharged eight days later with modest improvement in peripheral blood count.[Ref]

Gastrointestinal

Very common (10% or more): Nausea, vomiting, anorexia
Uncommon (0.1% to 1%): Pancreatitis, steatorrhea, diarrhea
Rare (less than 0.1%): Gastrointestinal ulcers (transplant recipients), intestinal hemorrhage (transplant recipients), necrosis (transplant recipients), colitis (transplant recipients), diverticulitis or intestinal perforation (transplant recipients), and severe diarrhea (inflammatory bowel disease patients)
Frequency not reported: Severe villus, sores in the mouth and on the lips[Ref]

Gastrointestinal side effects tend to be more problematic in the first few months of therapy. A 20-year-old man developed severe small-bowel villus atrophy and chronic diarrhea after starting azathioprine 50 mg per day. Diarrhea completely resolved within 2 weeks after azathioprine discontinuation. Mucosal biopsies at 4 months post azathioprine discontinuation showed complete reversal of severe duodenal villus atrophy.

Complications such as colitis, diverticulitis, and bowel perforation have been primarily reported in transplant patients, and may be related to concomitant high-dose corticosteroid therapy. Pancreatitis occurs most commonly in organ recipients and patients with Crohn's disease.

There have been case reports of patients with symptoms that imitate viral gastroenteritis (nausea, vomiting, diarrhea, and fever) occurring hours after a single dose of azathioprine.[Ref]

Oncologic

Common (1% to 10%): Squamous cell carcinoma of the skin, non-Hodgkin's lymphoma, cervical cancer, Kaposi's sarcoma, vulval cancer (renal homograft patients)
Uncommon (0.1% to 1%): Lymphoproliferative diseases after transplantation
Rare (0.01% to 0.1%): Melanoma, non-Kaposi's sarcoma
Very rare (less than 0.01%): Acute myeloid leukemia and myelodysplastic syndromes
Frequency not reported: Hepatosplenic T-cell lymphoma[Ref]

The increased risk of cancer may be more pronounced when azathioprine is used concomitantly with other immunosuppressive agents. Renal transplant patients may have a higher risk of developing lymphoproliferative disorders, lymphomas, and leukemia, as well as some solid tumors while receiving azathioprine.

Transplant patients as well as those with rheumatoid arthritis are often treated with multiple immunosuppressants; therefore, the true risk of neoplasia associated with azathioprine alone has yet to be determined.

A small increase in the risk of Epstein-Barr virus-positive lymphoma was seen in a study of patients with inflammatory bowel disease treated with azathioprine.

The majority of reported cases of hepatosplenic T-cell lymphoma have bee in patients with Crohn's disease or ulcerative colitis, and were adolescent and young adult males.[Ref]

Hepatic

Common (1% to 10%): hepatic dysfunction (including cholestasis, destructive cholangitis, peliosis hepatitis, perisinusoidal fibrosis, nodular regenerative hyperplasia) (organ transplant recipients)
Uncommon (0.1% to 1%): Hepatotoxicity, including elevation of serum alkaline phosphatase, bilirubin, and/or serum transaminases
Rare (Less than 0.1%): Life-threatening hepatic damage, hepatic veno-occlusive disease
Frequency not reported: Sinusoidal dilatation, acute focal hepatocellular necrosis, acute focal hepatocellular necrosis[Ref]

Hepatotoxicity usually occurs within the first six months of therapy and is more common in patients requiring immunosuppression following transplant than in patients requiring therapy for rheumatoid arthritis.

Hepatotoxicity is often manifest as cholestasis and/or acute focal hepatocellular necrosis, and is generally reversible following discontinuation of azathioprine therapy. However, permanent hepatic damage associated with cirrhosis, perisinusoidal fibrosis, hepatic peliosis, sinusoidal dilatation, and veno-occlusive disease is also reported. Several cases of nodular regenerative hyperplasia of the liver and at least one case of destructive cholangitis have been reported.

Veno-occlusive disease of the hepatic veins is due to an unknown mechanism, may affect males more often, usually precedes portal hypertension, and carries a poor prognosis. Numerous fatalities have been reported. Permanent discontinuation of azathioprine therapy is indicated if hepatic veno-occlusive disease is suspected.

A 51-year-old man developed jaundice and diffuse abdominal pain two months after the start of azathioprine 1.4 mg/kg/day. Biopsy reports confirmed destruction of the bile ducts consistent with destructive cholangitis. After discontinuation of azathioprine, the abdominal pain disappeared within 2 days and liver function tests improved and returned to normal values 8 weeks later.[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis
Very rare (less than 0.01%): Hypersensitivity reactions with fatal outcome[Ref]

Idiosyncratic manifestations of hypersensitivity include general malaise, headache, dizziness, nausea, vomiting, diarrhea, fever, rigors, exanthema, rash, vasculitis, myalgia, arthralgia, hypotension, renal dysfunction, hepatic dysfunction, cardiac dysrhythmia, and cholestasis. Rhabdomyolysis has been reported as part of an azathioprine hypersensitivity syndrome.

At least 3 cases of erythema nodosum, 2 cases of pustules, and 1 case of contact dermatitis have been reported. Erythema nodosum and pustules may be related to the clinical activity of inflammatory bowel disease. Relapse of such lesions shortly after rechallenge should raise the hypothesis of hypersensitivity rather than pharmacological manifestations.

Azathioprine should be permanently withdrawn after occurrence of hypersensitivity reactions.[Ref]

Cardiovascular

At least three cases of atrial fibrillation have been reported (one case involving a patient with ulcerative colitis), although causality is unknown. A 52-year-old male with steroid-dependent ulcerative colitis experienced atrial fibrillation coincident with azathioprine (the active ingredient contained in Imuran) therapy. The drug had been started 3 years earlier, but discontinued after a few months because the patient reported palpitations, lipothymia, nausea, and vomiting. Upon a rechallenge with 50 mg of azathioprine, the patient showed general malaise, nausea, and vomiting. An ECG showed atrial fibrillation, and the patient reported that the symptoms were similar to those experienced previously.

Azathioprine-induced hypotension is independent of dose and may accompany signs and symptoms of hypersensitivity. Hypotension may be profound, although it is usually responsive to intravenous fluids and, if hypersensitivity is suspected, corticosteroids.[Ref]

Rare (less than 0.01%): Hypotension, including cardiogenic shock
Frequency not reported: Atrial fibrillation[Ref]

Dermatologic

Alopecia has been reported in patients on azathioprine (the active ingredient contained in Imuran) monotherapy or in combination with other immunosuppressants. This side effect may resolve spontaneously despite ongoing therapy.

A female patient developed skin peeling syndrome eight months after the dosage of azathioprine was reduced to 25 mg daily. Skin lesions resolved 30 days after drug withdrawal.

Excess sun exposure, pale skin types, and duration of allograft seem to be important risk factors in the development of skin lesions.[Ref]

Common (1% to 10%): Alopecia
Frequency not reported: Skin rashes, Sweet's syndrome (acute febrile neutrophilic dermatosis), exacerbation of dermatomyositis[Ref]

Genitourinary

Rare (less than 0.1%): Hematuria secondary to azathioprine-induced crystalluria[Ref]

Immunologic

Very common (10% or more): Viral, fungal, and bacterial infections (transplant recipients also receiving other immunosuppressants)
Common (1% to 10%): Susceptibility to infection in patients with inflammatory bowel disease
Uncommon (0.1% to 1%): Viral, fungal, and bacterial infections (other indications)
Frequency not reported: Protozoal and opportunistic infections, including reactivation of latent infections, increased susceptibility to varicella and herpes zoster progressive multifocal leukoencephalopathy[Ref]

Metabolic

Frequency not reported: Negative nitrogen balance[Ref]

Musculoskeletal

Frequency not reported: Arthralgias, myalgias, exacerbation of myasthenia gravis[Ref]

Nervous system

Frequency not reported: Meningitis[Ref]

Ocular

Frequency not reported: CMV retinitis[Ref]

A patient with systemic lupus erythematosus and end-stage renal disease experienced CMV retinitis coincident with azathioprine therapy. It is theorized that immunosuppressive therapy may have a role in the development of CMV retinitis in this population. The patient responded to discontinuation of azathioprine, lowering of the corticosteroid dose, and systemic administration of ganciclovir.[Ref]

Renal

Elevation in serum creatinine and BUN accompanied by oliguria are usually associated with hypotension, and normalize after treatment with intravenous hydration and steroids. Cases of hematuria secondary to azathioprine-induced crystalluria may be less common with high urine output.

A reduction in the incidence of chronic allograft nephropathy has been reported during the extended follow-up (greater than or equal to 10 years) of patients (n=128) participating in a randomized trial that examined the conversion from cyclosporine to azathioprine (the active ingredient contained in Imuran) as early as three months after renal transplantation.

A 47-year-old female with Wegener's granulomatosis experienced rapid progression of renal failure within 10 days of starting azathioprine for vasculitis. Her creatinine was 119 mcmol/L at the time of presentation. Acute tubulointerstitial nephritis and no active glomerulonephritis were observed on renal biopsy. Her renal function started improving by day 6 post-admission and at one month post-admission her serum creatinine was 116 mcmol/L. She continued to have reasonable renal function and 16 months later had creatinine of 104 mcmol/L with no clinical evidence of recurrent interstitial nephritis.[Ref]

Frequency not reported: Elevation in serum creatinine and BUN accompanied by oliguria, chronic allograft nephropathy, acute interstitial nephritis[Ref]

Respiratory

Rare (less than 0.01%): Reversible interstitial pneumonitis[Ref]

Review of seven rare cases of azathioprine-associated interstitial pneumonitis revealed that the progression from alveolitis to pulmonary fibrosis may be dose-related.[Ref]

Other

There have been reports of fungal, protozoal, viral, and uncommon bacterial infections, some of which have been fatal, in patients who are receiving azathioprine (the active ingredient contained in Imuran) [Ref]

Frequency not reported: Fever, malaise, alterations in sense of smell or taste, delayed wound healing, oral lesions, fatigue[Ref]

References

1. Loftus CG, Loftus EV, Tremaine WJ, Sandborn WJ "The safety profile of Azathioprine (AZA)/6-Mercaptopurine (6-MP) in the treatment of inflammatory bowel disease (IBD): a population-based study in Olmsted County, Minnesota." Am J Gastroenterol 98(9S) (2003): S242

2. Konstantopoulou M, Belgi A, Griffiths KD, Seale JR, Macfarlane AW "Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase." BMJ 330 (2005): 350-1

3. Duran S, Apte M, Alarcon GS, et al. "Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort." Arthritis Rheum 59 (2008): 1332-1340

4. Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995): 114-6

5. Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992): 752-6

6. Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988): 503-5

7. Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989): 149-54

8. Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990): 69-72

9. Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995): 142-5

10. "Product Information. Imuran (azathioprine)." Glaxo Wellcome, Research Triangle Park, NC.

11. DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980): 377-9

12. Cerner Multum, Inc. "Australian Product Information." O 0

13. "Drugs for rheumatoid arthritis." Treat Guidel Med Lett 7 (2009): 37-46

14. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC "Long-term follow-up of patients with crohn's disease treated with azathioprine or 6-mercaptopurine." Lancet 347 (1996): 215-9

15. Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993): 1245-6

16. Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993): 85-7

17. Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982): 512-3

18. Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982): 44-7

19. Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993): 471

20. Escousse A, Mousson C, Santona L, Zanetta G, Mounier J, Tanter Y, Duperray F, Rifle G, Chevet D "Azathioprine-induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients: a family study." Transplant Proc 27 (1995): 1739-42

21. Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980): 927-8

22. Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988): 258-61

23. Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989): 837-43

24. Speerstra F, Boerbooms AM, van de Putte LB, et al "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982): 37-9

25. Tassaneeyakul W, Srimarthpirom S, Reungjui S, Chansung K, Romphruk A, Tassaneeyakul W "Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C." Transplantation 76 (2003): 265-6

26. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH "Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands." Am J Gastroenterol 94 (1999): 2417-22

27. Ziegler TR, Fernandez-Estivariz C, Gu LH, Fried MW, Leader LM "Severe villus atrophy and chronic malabsorption induced by azathioprine." Gastroenterology 124 (2003): 1950-7

28. Assini JF, Hamilton R, Strosberg JM "Adverse reactions to azathioprine mimicking gastroenteritis." J Rheumatol 13 (1986): 1117-8

29. Cox J, Daneshmend TK, Hawkey CJ, Logan RF, Walt RP "Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease." Gut 29 (1988): 686-8

30. Pozniak AL, Ahern M, Blake DR "Azathioprine-induced shock." Br Med J 283 (1981): 1548

31. Frick TW, Fryd DS, Goodale RL, Simmons RL, Sutherland DE, Najarian JS "Lack of association between azathioprine and acute pancreatitis in renal transplantation patients." Lancet 337 (1991): 251-2

32. Kawanishi H, Rudolph E, Bull FE "Azathioprine-induced acute pancreatitis." N Engl J Med 289 (1973): 357

33. Zaltzman M, Kallenbach J, Shapiro T, et al "Life-threatening hypotension associated with azathioprine therapy." S Afr Med J 65 (1984): 306

34. Floyd A, Pedersen L, Lauge Nielsen G, Thorlacius-Ussing O, Toft Sorensen H "Risk of acute pancreatitis in users of azathioprine: a population-based case-control study." Am J Gastroenterol 98 (2003): 1305-8

35. Barreto SG, Tiong L, Williams R "Drug-induced acute pancreatitis in a cohort of 328 patients. A single-centre experience from Australia." JOP 12 (2011): 581-5

36. Guillaume P, Grandjean E, Male PJ "Azathioprine-associated acute pancreatitis in the course of chronic active hepatitis." Dig Dis Sci 29 (1984): 78-80

37. Patel AA, Swerlick RA, McCall CO "Azathioprine in dermatology: the past, the present, and the future." J Am Acad Dermatol 55 (2006): 369-89

38. Amaro R, Neff GW, Karnam US, Tzakis AG, Raskin JB "Acquired hyperplastic gastric polyps in solid organ transplant patients." Am J Gastroenterol 97 (2002): 2220-4

39. Cochrane D, Adamson AR, Halsey JP "Adverse reactions to azathioprine mimicking gastroenteritis." 14 (1987): 1075

40. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA "Australian Adverse Drug Reactions Bulletin. Available from: URL: http://www.tga.gov.au/adr/aadrb/aadr0612.htm." ([2006 Dec]):

41. Silman AJ, Petrie J, Hazleman B, Evans SJ "Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study." Ann Rheum Dis 47 (1988): 988-92

42. Wilkinson AH, Smith JL, Hunsicker LG, et al "Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone." Transplantation 47 (1989): 293-6

43. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennardjones JE "Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease." Lancet 343 (1994): 1249-52

44. Krishnan K, Adams P, Silveira S, Sheldon S, Dabich L "Therapy-related acute myeloid leukaemia following immunosuppression with azathioprine for polymyositis." Clin Lab Haematol 16 (1994): 285-9

45. Or R, Kleinman Y, Chajek-Shaul T "Azathioprine and urinary bladder tumor." Ann Intern Med 99 (1983): 737

46. Tage-Jensen U, Schlichting P, Thomsen HF, et al "Malignancies following long-term azathioprine treatment in chronic liver disease." Liver 7 (1987): 81-3

47. Burger DC, Florin TH "Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease." Med J Aust 190 (2009): 341-2

48. Langer RM, Jaray J, Toth A, Hidvegi M, Vegso G, Perner F "De novo tumors after kidney transplantation: the budapest experience." Transplant Proc 35 (2003): 1396-8

49. Larvol L, Soule JC, Letourneau A "Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease." N Engl J Med 331 (1994): 883-4

50. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA "Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine." Br J Dermatol 133 (1995): 460-2

51. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. "Epstein-Barr Virus-Positive Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine or 6-Mercaptopurine." Gastroenterology 122 (2002): 72-77

52. Sobesky R, Dusoleil A, Condat B, Bedossa P, Buffet C, Pelletier G "Azathioprine-induced destructive cholangitis." Am J Gastroenterol 96 (2001): 616-7

53. Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986): 55-9

54. Liano F, Moreno A, Matesanz R, et al "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989): 509-16

55. Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992): 807-9

56. Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d'azathioprine." Gastroenterol Clin Biol 15 (1991): 968-73

57. Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989): 342-6

58. Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L "Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis." Gut 32 (1991): 715-7

59. Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990): 25-7

60. Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986): 446-54

61. Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989): 518-20

62. Read AE, Wiesner RH, LaBrecque DR, et al "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986): 651-5

63. Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973): 527-30

64. Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986): 171-3

65. DavidNeto E, daFonseca JA, dePaula FJ, Nahas WC, Sabbaga E, Ianhez LE "The impact of azathioprine on chronic viral hepatitis in renal transplantation: A long-term, single-center, prospective study on azathioprine withdrawal." Transplantation 68 (1999): 976-80

66. Sterneck M, Wiesner R, Ascher N, et al "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991): 806-10

67. Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987): 3699-703

68. DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984): 162-5

69. Cooper HL, Louafi F, Friedmann PS "A case of conjugal azathioprine-induced contact hypersensitivity." N Engl J Med 359 (2008): 1524-6

70. Bergman SM, Krane NK, Leonard G, Soto-Aguilar MC, WAllin JD "Azathioprine and hypersensitivity vasculitis." Ann Intern Med 109 (1988): 83-4

71. Carmichael DJ, Hamilton DV, Evans DB, Stovin PG, Calne RY "Interstitial pneumonitis secondary to azathioprine in a renal transplant patient." Thorax 38 (1983): 951-2

72. Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981): 1453-4

73. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

74. Saway PA, Heck LW, Bonner JR, Kirklin JK "Azathioprine hypersensitivity: case report and review of the literature." Am J Med 84 (1988): 960-4

75. Knowles SR, Gupta AK, Shear NH, Sauder D "Azathioprine hypersensitivity-like reactions - a case report and a review of the literature." Clin Exp Dermatol 20 (1995): 353-6

76. Cunningham T, Barraclough D, Muirden K "Azathioprine-induced shock." Br Med J 283 (1981): 823-4

77. El-Azhary RA, Brunner KL, Gibson LE "Sweet syndrome as a manifestation of azathioprine hypersensitivity." Mayo Clin Proc 83 (2008): 1026-30

78. Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982): 1388-9

79. Pandhi RK, Gupta LK, Girdhar M "Azathioprine-induced drug fever." Int J Dermatol 33 (1994): 198

80. de Fonclare AL, Khosrotehrani K, Aractingi S, Duriez P, Cosnes J, Beaugerie L "Erythema Nodosum-like Eruption as a Manifestation of Azathioprine Hypersensitivity in Patients With Inflammatory Bowel Disease." Arch Dermatol 143 (2007): 744-8

81. Major GA, Moore PG "Profound circulatory collapse due to azathioprine." J R Soc Med 78 (1985): 1052-3

82. Compton MR, Crosby DL "Rhabdomyolysis associated with azathioprine hypersensitivity syndrome." Arch Dermatol 132 (1996): 1254-5

83. Brown G, Boldt C, Webb JG, Halperin L "Azathioprine-induced multisystem organ failure and cardiogenic shock." Pharmacotherapy 17 (1997): 815-8

84. Dodd HJ, Tatnall FM, Sarkany I "Fast atrial fibrillation induced by treatment of psoriasis with azathioprine." Br Med J 291 (1985): 706

85. Cassinotti A, Massari A, Ferrara E, et al. "New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature." Eur J Clin Pharmacol 63 (2007): 875-8

86. HermannsLe T, Pierard GE "Azathioprine-induced skin peeling syndrome." Dermatology 194 (1997): 175-6

87. Shahnaz S, Choksi MT, Tan IJ "Bilateral cytomegalovirus retinitis in a patient with systemic lupus erythematosus and end-stage renal disease." Mayo Clin Proc 78 (2003): 1412-5

88. Benari Z, Mehta A, Lennard L, Burroughs AK "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis." J Hepatol 23 (1995): 351-4

89. Duttera MJ, Carolla RL, Gallelli JF, et al "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972): 292-4

90. Bir K, Herzenberg AM, Carette S "Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis." J Rheumatol 33 (2006): 185-7

91. McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993): 106

92. Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, De Fijter JW "Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy." Kidney Int 64 (2003): 1027-34

93. Krowka MJ, Breuer RI, Kehoe TJ "Azathioprine-associated pulmonary dysfunction." Chest 83 (1983): 696-8

94. Bedrossian CW, Sussman J, Conklin RH, Kahan B "Azathioprine-associated interstitial pneumonitis." Am J Clin Pathol 82 (1984): 148-54

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)